Login to Your Account



Analysts Focus on Lupus

Anthera'a Varespladib Fails: Biomarkers, Outcomes Differ

By Trista Morrison
Staff Writer

Tuesday, March 13, 2012
What was always known to be a high-risk, high-reward proposition proved to be more the former than the latter as Anthera Pharmaceuticals Inc.'s Phase III trial of varespladib was halted for futility.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription